SCHEMBL2295508

SCHEMBL2295508

COC(=O)C(NC(=O)c1nc(-c2ccc(NC(=S)NCc3ccccc3)cc2)no1)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.45
MAOB P27338 1/20 0.45
MAPT P10636 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMPD1 P17405 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295511 1.00 KMT2A (0.48) KMT2AMEN1HPGDALDH1A1MAOB
SCHEMBL2296852 0.91 MAPT (0.47) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2296857 0.91 MAPT (0.47) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2301331 0.90 SMN1; SMN2 (0.46) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2301343 0.90 SMN1; SMN2 (0.46) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2297977 0.83 CSGALNACT1 (0.46) KMT2AMEN1HPGDALDH1A1MAOB
SCHEMBL2297973 0.83 CSGALNACT1 (0.46) KMT2AMEN1HPGDALDH1A1MAOB
SCHEMBL2296122 0.82 DGAT1 (0.43) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2296119 0.82 DGAT1 (0.43) KMT2AMEN1HPGDALDH1A1MAPT
SCHEMBL2296821 0.78 CSGALNACT1 (0.53) KMT2AMEN1HPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT KMT2A 1450/4885MEN1 4530/4885HPGD 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.